Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Akiyuki YamamotoMasashi KatoHirotaka MatsuiRyo IshidaTohru KimuraYasuhito FunahashiNaoto SassaYoshihisa MatsukawaOsamu KamihiraRyohei HattoriMomokazu GotohToyonori TsuzukiPublished in: International journal of clinical oncology (2018)
The presence of IDC-P is an independent prognostic factor in CRPC patients with distant metastases and IDC-P in needle biopsies at the time of initial diagnosis. Docetaxel may prolong CSS and OS in CRPC patients with distant metastases and IDC-P in needle biopsies at the time of initial diagnosis.